The Neural Stem Cell Line CTX0E03 Promotes Behavioral Recovery and Endogenous Neurogenesis After Experimental Stroke in a Dose-Dependent Fashion

Stroemer, Paul; Patel, Sara; Hope, Andrew; Oliveira, Cathy; Pollock, Kenny; Sinden, John D.

doi:10.1177/1545968309335978

Cited by 135 publications

(130 citation statements)

References 25 publications

Supporting

Mentioning

122

Contrasting

Order By: Relevance

“…The FDA recently granted approval to initiate a Phase I safety evaluation for MultiStem infusion at day 2 following ischemic stroke. That clinical study as well as the evaluation of bone marrow mononuclear cells (Savitz 2009) or gene modified neuronal stem cells (Stroemer et al 2009) will comprise an important translational dataset to resolve this important unmet clinical need.…”

Section: Discussionmentioning

confidence: 99%

Development of an allogeneic adherent stem cell therapy for treatment of ischemic stroke

Mays¹,

Borlongan²,

Yasuhara³

et al. 2010

J Exp Stroke Transl Med

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Development of an allogeneic adherent stem cell therapy for treatment of ischemic stroke

Mays¹,

Borlongan²,

Yasuhara³

et al. 2010

J Exp Stroke Transl Med

View full text Add to dashboard Cite

“…Preclinical stroke model data reported dose dependent improvements in sensorimotor recovery over 12 weeks post-implantation when delivered 3-5 weeks after middle cerebral artery occlusive stroke in the rat. 46 In PISCES 1, eleven male patients underwent implantation a median of 22 months after stroke. No cell-related safety issues were observed, with serious adverse events being related either to the neurosurgical procedure or to long-term consequences of stroke comorbidities.…”

Section: Late Subacute or Chronic Strokementioning

confidence: 99%

Clinical trial design for stem cell therapies in stroke: What have we learned?

Muir

2017

Neurochemistry International

View full text Add to dashboard Cite

Stem cells of various sources have been investigated in a series of small, safety and feasibility-focused studies over the past 15 years. Understanding of mechanisms of action has evolved and the trial paradigms have become focused on two different approaches -one being an early subacute delivery of cells to reduce acute tissue injury and modify the tissue environment in a direction favourable to reparative processes (for example by being anti-inflammatory, antiapoptotic, and encouraging endogenous stem cell mobilisation); the other exploring later delivery of cells during the recovery phase after stroke to modulate the local environment in favour of angiogenesis and neurogenesis. The former approach has generally investigated intravenous or intra-arterial delivery of cells with an expected paracrine mode of action and no expected engraftment within the brain. The latter has explored direct intracerebral implantation adjacent to the infarct. Several relevant trials have been conducted, including two controlled trials of intravenously delivered bone marrow-derived cells in the early subacute stage, and two small singlearm phase 1 trials of intracerebrally implanted cells. The findings of these studies and their implications for future trial design are considered.Introduction:

show abstract

“…Cell therapy for stroke has tested several types of transplantable cells in the laboratory, with a few reaching clinical trials, such as fetal cells, NT2N cells, CTX0E3, embryonic stem cells, neural stem/progenitor cells, umbilical cord blood, amnion, adipose, and induced pluripotent stem cells [67][68][69][70][71][72]. Compared to these other stem cells, MSCs have established a solid safety profile in other disease indications, providing the basis for on-going clinical trials to explore MSCs and their cell subpopulations [73,74].…”

Section: Mscs Their Mechanism Of Action and Safety Profilementioning

confidence: 99%

Mesenchymal stem cell-based therapy for ischemic stroke

et al. 2016

View full text Add to dashboard Cite

Ischemic stroke represents a major, worldwide health burden with increasing incidence. Patients affected by ischemic strokes currently have few clinically approved treatment options available. Most currently approved treatments for ischemic stroke have narrow therapeutic windows, severely limiting the number of patients able to be treated. Mesenchymal stem cells represent a promising novel treatment for ischemic stroke. Numerous studies have demonstrated that mesenchymal stem cells functionally improve outcomes in rodent models of ischemic stroke. Recent studies have also shown that exosomes secreted by mesenchymal stem cells mediate much of this effect. In the present review, we summarize the current literature on the use of mesenchymal stem cells to treat ischemic stroke. Further studies investigating the mechanisms underlying mesenchymal stem cells tissue healing effects are warranted and would be of benefit to the field.

show abstract

The Neural Stem Cell Line CTX0E03 Promotes Behavioral Recovery and Endogenous Neurogenesis After Experimental Stroke in a Dose-Dependent Fashion

Cited by 135 publications

References 25 publications

Development of an allogeneic adherent stem cell therapy for treatment of ischemic stroke

Development of an allogeneic adherent stem cell therapy for treatment of ischemic stroke

Clinical trial design for stem cell therapies in stroke: What have we learned?

Mesenchymal stem cell-based therapy for ischemic stroke

Contact Info

Product

Resources

About